Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Fineline Cube Jun 16, 2026
Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Fineline Cube Jun 16, 2026
Company Drug

Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC

Fineline Cube Aug 16, 2022

China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...

Company Drug

Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Aug 15, 2022

Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...

Company

EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs

Fineline Cube Aug 15, 2022

US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...

Company

Novartis Aims for China to Be Second – Largest Market by 2024

Fineline Cube Aug 15, 2022

Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...

Company Deals R&D

ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition

Fineline Cube Aug 15, 2022

Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first...

Company Deals Digital

ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China

Fineline Cube Aug 15, 2022

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with...

Company Deals

E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products

Fineline Cube Aug 15, 2022

E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed...

Company Deals Digital Hospital

KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions

Fineline Cube Aug 15, 2022

Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a...

Company Drug

Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China

Fineline Cube Aug 15, 2022

China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...

Company Deals

Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development

Fineline Cube Aug 15, 2022

Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an...

Company Drug

Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study

Fineline Cube Aug 15, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Company Drug

Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer

Fineline Cube Aug 15, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...

Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Fineline Cube Aug 12, 2022

Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...

R&D

Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients

Fineline Cube Aug 12, 2022

A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted...

Company Deals

Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem

Fineline Cube Aug 12, 2022

Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...

Company Deals

Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech

Fineline Cube Aug 12, 2022

Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...

Company Deals

WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production

Fineline Cube Aug 12, 2022

WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...

Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Posts pagination

1 … 655 656 657 … 684

Recent updates

  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
  • BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications
  • Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers
  • AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Others

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.